login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
FULCRUM THERAPEUTICS INC (FULC) Stock News
USA
-
Nasdaq
- NASDAQ:FULC -
US3596161097
-
Common Stock
8.76
USD
-0.3 (-3.31%)
Last: 12/4/2025, 8:24:51 PM
8.76
USD
0 (0%)
After Hours:
12/4/2025, 8:24:51 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
FULC Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
3 days ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
15 days ago - By: Zacks Investment Research
- Mentions:
ALKS
AGIO
CRMD
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
17 days ago - By: Benzinga
- Mentions:
NICE
HD
HP
HTHT
...
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
a month ago - By: Benzinga
- Mentions:
CGO
ROL
ESRT
NNBR
...
Earnings Scheduled For October 29, 2025
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
2 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
2 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
2 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Please enable JavaScript to continue using this application.